Overall clinical experience with aztreonam in the treatment of obstetric-gynecologic infections.

Gynecologic infections (primarily endometritis and pelvic inflammatory disease) in 73 women were evaluated for clinical and microbiologic response to treatment with aztreonam plus clindamycin or a control regimen. The dosage of aztreonam used most frequently was 1 g three times daily. For 72 of the 73 women, a microbiologic cure and a satisfactory clinical response were achieved. Twenty-three of the 73 patients were treated with aztreonam in an open study; all experienced a microbiologic cure and a favorable clinical response. Fifty of the 73 patients treated with aztreonam plus clindamycin were entered into a comparative study that included 38 patients who received gentamicin (3-5 mg/kg per day) plus clindamycin (600 mg three times a day). In 49 (98%) of the aztreonam-treated patients and in 36 (95%) of the gentamicin-treated patients, the causative organism was eradicated, and in 98% and 89% of the patients, respectively, a favorable clinical response was achieved.

RCT Entities:   Population Interventions Outcomes